Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Valeant’s Retigabine Accepted for Review | Contract Pharma

What are you searching for?

Sign in

Valeant’s Retigabine Accepted for Review

Valeant Pharmaceuticals’ NDA for the investigational drug retigabine has been accepted for review by the FDA.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Valeant Pharmaceuticals’ NDA for the investigational drug retigabine has been accepted for review by the FDA. Retigabine is a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures.

Additionally, the company’s MAA was successfully validated by the EMEA on November 17, 2009. The filings were submitted on October 30, 2009.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters